DOI: 10.36347/sjams.2017.v05i06.038

Pages: 2242-2255

There were claims that second generation antipsychotics (SGA) produce fewer extra-pyramidal symptoms (EPS) and their EPS profiles were compared. The aim is to compare the treatment emergent EPS and efficacy profile between olanzapine, risperidone, iloperidone and asenapine in people with psychoticdisorders. The clinical comparative study was undertaken at Department of Psychiatry, Sri Venkateshwara Ramnarayana Ruia Hospital, Tirupathi. Total 120 patients diagnosed to be suffering from psychotic disorders were enrolled in this study after obtainedwritten informed consent. They are treated alternately primarily with the 4 drugs i.e. olanzapine, risperidone, iloperidone and asenapine. They were regularly followed-up for 3 months for EPS and efficacy by using standardized rating scales.Patients were requested to attend regular follow-ups at 2 weeks, 4 weeks,8weeks and 12 weeks interval. Iloperidone dose was titrated over 6-10 days to reach its maximum dose. Specific instructions were given for asenapine in its sublingual administration. There were no significant differences in occurrence or changes in rating scales for parkinsonism, akathisia or tardive dyskinesia among the 4 drugs. There were also no significant differences in change in BPRS scores from baseline among the 4 drugs. The occurrence of treatment emergent EPS and changes in EPS rating scales indicated that all the 4 drugs were similar to each other in causing EPS. Regarding efficacy, this study concludes that all the 4 drugs were similar to each other in their efficacy profile in treatment of psychotic disorders.